华蟾素片在结直肠癌术后患者化疗中的应用效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effect of Huachansu Tablets in chemotherapy for postoperative patients with colorectal cancer.Methods A total of 122 cases of postoperative patients with colorectal cancer treated in our hospital from January 2018 to January 2019 were selected as the research objects.They were divided into study group (Huachansu Tablets combined with XELOX regimen treatment) and control group (XELOX regimen treatment), 61 cases in each group.The quality of life (KPS) scores, carcinoembryonic antigen (CEA) levels before and after treatment,and the incidence of adverse reactions of patients were compared between the two groups.Results There was no significant difference in KPS score between the two groups before treatment (t=0.097, P＞0.05).After treatment, the KPS score of the study group was (82.64±6.47) points, which was higher than that of the control group of (76.41±5.47)points, the difference was statistically significant (t=5.743, P＜0.05).The CEA levels of the two groups before treatment had no statistically significant difference (t=0.043, P＞0.05), and the CEA of the study group after treatment was (2.78±0.66 ) μg/ml, which was lower than that of the control group of (3.97±1.33) μg/ml, the difference was statistically significant (t=6.260, P＜0.05).The total incidence of adverse reactions in the study group was lower than that in the control group, and the difference was statistically significant (P＜0.05).Conclusion The treatment of colorectal cancer patients undergoing chemotherapy with Huachansu Tablets combined with XELOX regimen can improve the quality of life and chemotherapy effect of patients, reduce adverse reactions, and have high clinical application value.

Key words： Colorectal cancer Chemotherapy XELOX regimen Huachansu Tablets

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Ming-wei

Cite this article:

WANG Ming-wei. Application effect of Huachansu Tablets in chemotherapy for postoperative patients with colorectal cancer[J]. 中国当代医药, 2020, 27(22): 91-93.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I22/91

[1]	张德志，刘猛，朱少功.PD-L1 表达对术后接受氟尿嘧啶用药方案为基础辅助化疗的结直肠癌患者预后影响[J].中国现代医药杂志，2019，21（11）：20-24.
[2]	张慧俭，刘佃温，周晓丽，等.PD-L1 基因rs2297136 位点多态性对术后结直肠癌患者接受卡培他滨为基础辅助化疗预后的影响[J].中国癌症杂志，2019，29（10）：795-802.
[3]	缪娴，陶玉华，顾小侠，等.济生散联合术后辅助化疗对Ⅱ期结直肠癌的疗效及对肠道菌群的影响[J].中国肿瘤外科杂志，2019，11（5）：346-349.
[4]	吕俊杰.分析华蟾素片对晚期肺癌患者凝血状态、治疗效果及生活质量的影响[J].中国医药指南，2019，17（12）：194.
[5]	李爱峰，印海林，蔺梅，等.华蟾素片联合SOX 方案治疗晚期胃癌的临床研究[J].现代药物与临床，2019，34（3）：714-718.
[6]	史延江，李赟，赵娜.华蟾素胶囊联合化疗治疗Ⅲ期结肠癌术后患者的疗效[J].中国肿瘤临床与康复，2017，24（9）：1078-1081.
[7]	应金龙，徐积春.多层螺旋CT 检查评价益气扶正祛邪方联合化疗在原发性结直肠癌术后的应用效果[J].中国中医药科技，2019，26（4）：629-631.
[8]	张艳.Ⅲ期结直肠癌术后辅助化疗时长对患者生存期的影响[D].沈阳：中国医科大学，2019.
[9]	肖刘牛，朱丽，陈颖铭，等.Ⅱ期结直肠癌术后化疗临床预后危险因素的Meta 分析[J].循证医学，2019，19（3）：167-177.
[10]	王俊伟，金心富，卢凯.腹腔镜切除术配合FOLFOX4 新辅助化疗对直肠癌患者血清FAS、Tu M2-PK 及T 细胞亚群的影响[J].临床和实验医学杂志，2019，18（9）：981-985.
[11]	迪米拉·阿里根，帕尔哈提·阿布都热衣木，张丽博.双歧杆菌三联活菌辅助XELOX 方案对结直肠癌术后抗肿瘤免疫应答和肿瘤标志物的影响[J].中国临床研究，2019，32（4）：516-519.
[12]	黄水仙，蔡徐杰，吴江洪，等.胸腺五肽联合奥沙利铂和卡培他滨方案在直肠癌术后患者辅助化疗中的应用效果[J].中国当代医药，2019，26（11）：64-66.
[13]	史钟，郁肖夫，朱静，等.结直肠癌术后患者化疗前后外周血NKT 及NK 细胞表达分析[J].中国现代医生，2019，57（10）：86-89.
[14]	冯宝约，杨莹，王超然，等.华蟾素注射液抗结肠癌移植瘤血管新生的作用研究[J].中国医药导报，2018，15（20）:4-7，24，封3.
[15]	陈力，黄学锋.阳性淋巴结比值比在预测术前放化疗后直肠癌术后患者生存的价值[J].中国实用医药，2019，14（1）：1-6.
[16]	范圣涛.FOLFOX 方案化疗联合参麦注射液在治疗结直肠癌术后患者的临床疗效分析[J].中医临床研究，2019，11（1）：91-92.
[17]	刘世举，张慧俭，王金榜，等.结直肠癌术后辅助卡培他滨为基础化疗方案的临床疗效及相关药物基因组学分析[J].中国肿瘤临床，2018，45（17）：889-893.
[18]	林毅，王振飞，王智健，等.华蟾素片联合XELOX 方案对结直肠癌术后化疗的临床观察[J].中国中医药现代远程教育，2017，15（22）：107-109.